REG - Haleon PLC - Completion of off-market purchase and Total Voting

HALEONAnnouncement

21/03/2025 11:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250321:nRSU6955Ba&default-theme=true

RNS Number : 6955B  Haleon PLC  21 March 2025

 

Haleon plc: Completion of off-market purchase and Total Voting Rights and
Capital

 

21 March 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today
announces that it has completed the off-market purchase of 44,155,844 ordinary
shares of £0.01 each, repurchased from Pfizer Inc. for an aggregate purchase
price of approximately £170 million. The purchased ordinary shares have been
cancelled.

As at 21 March 2025, the total number of ordinary shares issued by Haleon is
9,039,570,075, of which 4,080,205 are held as treasury shares. Therefore, the
number of ordinary shares with voting rights is 9,035,489,870 and this figure
may be used by shareholders (and others with notification obligations) as the
denominator for the calculation by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

Amanda Mellor

Company Secretary

 

 

Enquiries

 

 Investors                                                                           Media

 Jo Russell                                +44 7787 392441                           Zoë Bird                               +44 7736 746167
 Rakesh Patel                              +44 7552 484646                           Victoria Durman                        +44 7894 505730
 Emma White                                +44 7823 523562

 Email: investor-relations@haleon.com (mailto:investor-relations@haleon.com)         Email: corporate.media@haleon.com (mailto:corporate.media@haleon.com)

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans five major categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
Otrivin, Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.

 

For more information please visit www.haleon.com (http://www.haleon.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCJBMMTMTATBJA